Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2519 | Placebo solution Wiki | 0.58 |
drug1998 | Methylprednisolone Sodium Succinate Wiki | 0.41 |
drug1771 | Leronlimab (700mg) Wiki | 0.33 |
Navigate: Correlations HPO
There are 3 clinical trials
This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years old and above.
This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years old and above.
This is a randomized, double-blinded, placebo controlled phase III clinical trial to evaluate the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above after 2-dose schedule.
Description: The incidence of the symptomatic and laboratory-confirmed COVID-19 cases starting from Day 14 after the second dose.
Measure: The incidence of COVID-19 cases after two-doses of vaccination Time: From 14 days after the second dose to 1 year after the second dose.Description: The incidence of solicited AEs at the inoculation site (local) and solicited AEs at the non-inoculation site (systemic) within 7 days after each dose
Measure: The incidence of solicited AEs. Time: 7 days after each doseDescription: The incidence of the symptomatic and laboratory-confirmed COVID-19 cases after at least one dose of immunization.
Measure: The incidence of COVID-19 cases after at least one dose of immunization. Time: From the first dose to 1 year after the second dose.Description: The Geometric Mean Titer (GMT) of neutralizing antibody against SARS-CoV-2 14 days after the whole-course immunization.
Measure: The Geometric Mean Titer (GMT) of neutralizing antibody Time: 14 days after the whole-course immunizationDescription: The Geometric Mean Titer (GMT) of IgG antibody (ELISA method) against SARS-CoV-2 14 days after the whole-course immunization.
Measure: The Geometric Mean Titer (GMT) of IgG antibody Time: 14 days after the whole-course immunizationDescription: The positive rates of neutralizing antibody against SARS-CoV-2 14 days after the whole-course immunization.
Measure: The positive rates of neutralizing antibody Time: 14 days after the whole-course immunizationDescription: The positive rates of IgG antibody (ELISA method) against SARS-CoV-2 14 days after the whole-course immunization.
Measure: The positive rates of IgG antibody Time: 14 days after the whole-course immunizationDescription: The seroconversion rates of neutralizing antibody against SARS-CoV-2 14 days after the whole-course immunization.
Measure: The seroconversion rates of neutralizing antibody Time: 14 days after the whole-course immunizationDescription: The seroconversion rates of IgG antibody (ELISA method) against SARS-CoV-2 14 days after the whole-course immunization.
Measure: The seroconversion rates of IgG antibody Time: 14 days after the whole-course immunizationDescription: The positive rates of neutralizing antibody against SARS-CoV-2 6 months and 12 months after whole-course immunization.
Measure: The positive rates of neutralizing antibody Time: 6 months and 12 months after whole-course immunization.Description: The positive rates of IgG antibody (ELISA method) against SARS-CoV-2 6 months and 12 months after whole-course immunization.
Measure: The positive rates of IgG antibody Time: 6 months and 12 months after whole-course immunization.Description: The Geometric Mean Titer (GMT) of neutralizing antibody against SARS-CoV-2 6 months and 12 months after whole-course immunization.
Measure: The Geometric Mean Titer (GMT) of neutralizing antibody Time: 6 months and 12 months after whole-course immunization.Description: The Geometric Mean Titer (GMT) of IgG antibody (ELISA method) against SARS-CoV-2 6 months and 12 months after whole-course immunization.
Measure: The Geometric Mean Titer (GMT) of IgG antibody Time: 6 months and 12 months after whole-course immunization.Description: Detecting specific T cells with ELISPOT assay 6 months and 12 months after the whole-course immunization
Measure: Specific T cells with ELISPOT assay Time: 6 months and 12 months after the whole-course immunizationDescription: The incidence of AEs from the first dose to 28 days after whole-course immunization
Measure: The incidence of AEs Time: From the first dose to 28 days after whole-course immunization.Description: The incidence of SAEs from the first dose to at least 12 months after whole-course immunization.
Measure: The incidence of SAEs Time: From the first dose to at least 12 months after whole-course immunization.Description: The occurrence of Antibody Dependent Enhancement (ADE)/ Vaccine Enhanced Disease(VED) that probably related to the laboratory-confirmed COVID-19 from 14 days after the second dose till the end of trial.
Measure: The occurrence of Antibody Dependent Enhancement (ADE)/ Vaccine Enhanced Disease(VED) Time: From 14 days after the second dose to 1 year after the second dose.Description: The correlation between the efficacy of the vaccine and the levels of neutralizing antibody and IgG antibody against SARS-CoV-2.
Measure: The surrogate endpoint of immunogenicity Time: From 14 days after the second dose to 1 year after the second dose.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports